DBPR108

DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9. IC50 value: 15 nM [1] Target: DPP4 inhibitor DBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including inhibition of plasma DPP-IV activity and suppression of blood glucose elevation, were also demonstrated. DBPR108 is a potent, selective, long-acting and safe DPP-IV inhibitor as a potential treatment of type 2 diabetes mellitus.

Product Specifications

CAS Number

[1186426-66-3]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Dipeptidyl Peptidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/DBPR108.html

Purity

99.93

Solubility

DMSO : ≥ 25 mg/mL

Smiles

N#C[C@H]1N(C(CNC(C)(C)CC(N2CCCC2)=O)=O)C[C@@H](F)C1

Molecular Formula

C16H25FN4O2

Molecular Weight

324.39

Precautions

H315, H319, H335

References & Citations

[1]Yeh TK, et al. (2S,4S) -1-[2- (1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino) acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. Bioorg Med Chem Lett. 2010 Jun 15;20 (12) :3596-600.